ADC Therapeutics SA
NYSE:ADCT
ADC Therapeutics SA
Accounts Payable
ADC Therapeutics SA
Accounts Payable Peer Comparison
Competitive Accounts Payable Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ADC Therapeutics SA
NYSE:ADCT
|
Accounts Payable
$15.6m
|
CAGR 3-Years
43%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
AC Immune SA
NASDAQ:ACIU
|
Accounts Payable
CHf1.7m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Accounts Payable
$38.1m
|
CAGR 3-Years
61%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Accounts Payable
CHf5.8m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
13%
|
|
Idorsia Ltd
SIX:IDIA
|
Accounts Payable
CHf25.4m
|
CAGR 3-Years
43%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
Kuros Biosciences AG
SIX:KURN
|
Accounts Payable
CHf1.3m
|
CAGR 3-Years
12%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
See Also
What is ADC Therapeutics SA's Accounts Payable?
Accounts Payable
15.6m
USD
Based on the financial report for Dec 31, 2023, ADC Therapeutics SA's Accounts Payable amounts to 15.6m USD.
What is ADC Therapeutics SA's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
18%
Over the last year, the Accounts Payable growth was 26%. The average annual Accounts Payable growth rates for ADC Therapeutics SA have been 43% over the past three years , 18% over the past five years .